Blog
RSS FeedPosted by Michael Wonder on 22 Aug 2019
Sir Andrew Dillon to stand down as NICE chief executive
22 August 2019 - Sir Andrew Dillon has announced his intention to stand down as NICE chief executive next year. ...
Posted by Michael Wonder on 22 Aug 2019
ABPI position on US trade deal and medicines pricing
21 August 2019 - In response to concerns about the impact a US trade deal would have on medicine pricing, ...
Posted by Michael Wonder on 21 Aug 2019
NICE’s fast-track catapults Skyrizi into market
21 August 2019 - Watchdog also gives direction on comparing rival treatments. ...
Posted by Michael Wonder on 21 Aug 2019
NHS to reimburse Hemlibra
21 August 2019 - NHS England has commissioned Roche and Chugai’s joint haemophilia A drug, Hemlibra (emicizumab), agreeing to fund ...
Posted by Michael Wonder on 20 Aug 2019
NICE’s track record in cancer drugs: the impact of the CDF and interim funding
20 August 2019 - Cancer drugs and the decisions made by the UK’s NICE have been subject to much scrutiny ...
Posted by Michael Wonder on 18 Aug 2019
Great Britain faces food, fuel and medicine shortages in no-deal Brexit, official leaked papers say
19 August 2019 - Britain will face shortages of fuel, food and medicine if it leaves the European Union without ...
Posted by Michael Wonder on 15 Aug 2019
Advanced ovarian cancer drug gets initial 'no' for NHS in England
15 August 2019 - A targeted drug with potential to slow the progress of ovarian cancer has been rejected for ...
Posted by Michael Wonder on 15 Aug 2019
Government to set up ‘express freight service’ for medicinal products in event of no-deal Brexit
15 August 2019 - Additional preparation to ensure continuity of supplies. ...
Posted by Michael Wonder on 14 Aug 2019
Drug company Aspen may pay NHS £8 million after investigation alleges illegal deal to hike drug price
14 August 2019 - The drug company Aspen may have to pay the NHS £8 million (€8.7 million ; $9.7 ...
Posted by Michael Wonder on 12 Aug 2019
Drug maker 'will make $21 billion from treating cystic fibrosis'
12 August 2019 - Vertex is accused of raking in vast profits while making Orkambi unaffordable to NHS. ...
Posted by Michael Wonder on 12 Aug 2019
Is rate of return pricing a useful approach when value based pricing is not appropriate?
12 August 2019 - The pricing of new health technologies, such as drugs or devices, involves deciding how the economic ...
Posted by Michael Wonder on 11 Aug 2019
Watchdog declines to back NHS cannabis treatment for epilepsy
8 August 2019 - NICE draft guidance and NHS England review highlight need for more research on cannabis-based medicinal products.
...
Posted by Michael Wonder on 08 Aug 2019
NICE draft guidance and NHS England review highlight need for more research on cannabis-based medicinal products
8 August 2019 - The fast-tracked guidance follows the re-classification of these products last year to allow specialist doctors to ...
Posted by Michael Wonder on 08 Aug 2019
New lung cancer treatment option approved by NICE
8 August 2019 - Another new life-extending treatment for some people with lung cancer is to be made available on the ...
Posted by Michael Wonder on 07 Aug 2019
NICE recommends additional treatment option for people with early breast cancer
7 August 2019 - NICE has today published draft guidance recommending neratinib as an additional treatment for some people with early ...